Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

46 trials with published results (11%)

Research Maturity

158 completed trials (39% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

4.9%

20 terminated out of 407 trials

Success Rate

88.8%

+2.2% vs benchmark

Late-Stage Pipeline

6%

23 trials in Phase 3/4

Results Transparency

29%

46 of 158 completed with results

Key Signals

46 with results89% success20 terminated

Data Visualizations

Phase Distribution

253Total
Not Applicable (114)
Early P 1 (3)
P 1 (39)
P 2 (74)
P 3 (14)
P 4 (9)

Trial Status

Completed158
Recruiting86
Unknown75
Active Not Recruiting30
Not Yet Recruiting27
Terminated20

Trial Success Rate

88.8%

Benchmark: 86.5%

Based on 158 completed trials

Clinical Trials (407)

Showing 20 of 20 trials
NCT05355701Phase 1Recruiting

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

NCT06991738Phase 1Not Yet RecruitingPrimary

177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer

NCT05538130Phase 1Recruiting

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

NCT01833650Not ApplicableCompletedPrimary

The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer

NCT06959511Phase 2Recruiting

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

NCT06411834Not ApplicableNot Yet RecruitingPrimary

Mapping Patient Decision-making in Thyroid Cancer

NCT07124000Recruiting

DESTINY-PANTUMOUR04

NCT01141309Phase 2Active Not RecruitingPrimary

Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer

NCT07234539Not ApplicableEnrolling By InvitationPrimary

Evaluation of an Artificial Intelligence-enabled Clinical Assistant to Support Thyroid Cancer Management

NCT07707401Not ApplicableRecruiting

Effectiveness of WeChat-Supported Neck Rehabilitation Exercises on Early Recovery After Thyroidectomy

NCT07704658Phase 4Recruiting

Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors

NCT07705074Phase 1Not Yet Recruiting

FAPI PET Imaging - An Exploratory Study

NCT07690839Not ApplicableNot Yet RecruitingPrimary

Pre-Clinic Visit Online Education for Thyroid Cancer

NCT03345563Not ApplicableCompleted

Project HERO: Health Empowerment & Recovery Outcomes

NCT04238624Phase 2Active Not Recruiting

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

NCT07406087Not ApplicableRecruiting

Navigation Intervention for Adolescent and Young Adult Cancer Survivors

NCT04000880Not ApplicableCompleted

Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health

NCT03841617Phase 2RecruitingPrimary

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

NCT07428057Recruiting

Postoperative Hypocalcemia After Thyroidectomy

NCT02012699Recruiting

Integrated Cancer Repository for Cancer Research

Scroll to load more

Research Network

Activity Timeline